TR200101417T2 - Sefuroksim aksetil içeren kompozisyonlar. - Google Patents

Sefuroksim aksetil içeren kompozisyonlar.

Info

Publication number
TR200101417T2
TR200101417T2 TR2001/01417T TR200101417T TR200101417T2 TR 200101417 T2 TR200101417 T2 TR 200101417T2 TR 2001/01417 T TR2001/01417 T TR 2001/01417T TR 200101417 T TR200101417 T TR 200101417T TR 200101417 T2 TR200101417 T2 TR 200101417T2
Authority
TR
Turkey
Prior art keywords
cefuroxime axetil
compositions containing
containing cefuroxime
production
axetil
Prior art date
Application number
TR2001/01417T
Other languages
English (en)
Inventor
Jennewein Herwig
Raneburger Johannes
Original Assignee
Biochemie Gesellschaft M.B.H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemie Gesellschaft M.B.H filed Critical Biochemie Gesellschaft M.B.H
Publication of TR200101417T2 publication Critical patent/TR200101417T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Sulu bir sivi ile temas halinde, jelatinimsi-olmayan bir formda, mesela, bir polimer içinde kati bir çözelti formunda veya mesela, aktif bir muhteviyat olarak sefuroksim aksetil içeren farmasötik kompozisyonlarin üretimi için faydali olan bir tasiyici üzerinde, kati bir dispersiyon formunda sefuroksim aksetil ve ters bir besin etkisi sergilemeyen bir oral dozaj formunun üretiminde, sefuroksim aksetilin kullanimi.
TR2001/01417T 1998-11-26 1999-11-24 Sefuroksim aksetil içeren kompozisyonlar. TR200101417T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Publications (1)

Publication Number Publication Date
TR200101417T2 true TR200101417T2 (tr) 2001-11-21

Family

ID=3525440

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01417T TR200101417T2 (tr) 1998-11-26 1999-11-24 Sefuroksim aksetil içeren kompozisyonlar.

Country Status (30)

Country Link
US (1) US6727243B1 (tr)
EP (1) EP1133298B1 (tr)
JP (1) JP2002530338A (tr)
KR (1) KR20010080566A (tr)
CN (1) CN1330546A (tr)
AR (1) AR021405A1 (tr)
AT (3) AT413647B (tr)
AU (1) AU759517B2 (tr)
BR (1) BR9915694A (tr)
CA (1) CA2348876A1 (tr)
CO (1) CO5190668A1 (tr)
CZ (1) CZ20011845A3 (tr)
DE (1) DE69935609T2 (tr)
ES (1) ES2285866T3 (tr)
HU (1) HUP0104412A3 (tr)
ID (1) ID28615A (tr)
IL (1) IL142762A0 (tr)
MY (1) MY129564A (tr)
NO (1) NO20012526L (tr)
NZ (1) NZ511588A (tr)
PE (1) PE20001326A1 (tr)
PL (1) PL348744A1 (tr)
RU (1) RU2248794C2 (tr)
SI (1) SI1133298T1 (tr)
SK (1) SK7162001A3 (tr)
TR (1) TR200101417T2 (tr)
TW (1) TWI229603B (tr)
WO (1) WO2000030647A1 (tr)
YU (1) YU34601A (tr)
ZA (1) ZA200103927B (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001230490A1 (en) * 2000-12-01 2002-06-11 Arun Shriniwas Gosavi Pharmaceutical formulation
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
CZ12993U1 (cs) * 2001-11-23 2003-02-10 Glaxo Group Limited Farmaceutický prostředek
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
KR100552567B1 (ko) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
EP2579859B1 (en) 2010-06-14 2015-08-05 ratiopharm GmbH Solid ivabradine-containing composition
WO2014023710A1 (en) * 2012-08-07 2014-02-13 Sandoz Ag UNCOATED TABLET COMPRISING GRANULES INCLUDING A β-LACTAM ANTIBIOTIC AND HIGHLY DISPERSED SILICONE DIOXIDE
US9603804B2 (en) 2013-04-25 2017-03-28 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2014174847A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
US10154993B2 (en) 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1572993A (en) * 1976-02-16 1980-08-13 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
DE19602757A1 (de) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
JP2002511777A (ja) * 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
ATE232728T1 (de) * 1998-03-03 2003-03-15 Dae Woong Pharma Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
CA2239331C (en) 1998-05-29 1999-11-30 Bernard Charles Sherman Pharmaceutical tablets comprising cefuroxime axetil
DE19835823A1 (de) 1998-08-10 1999-10-07 Lindopharm Gmbh Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
CO5190668A1 (es) 2002-08-29
WO2000030647A1 (en) 2000-06-02
ID28615A (id) 2001-06-21
HUP0104412A2 (hu) 2002-04-29
PL348744A1 (en) 2002-06-03
MY129564A (en) 2007-04-30
BR9915694A (pt) 2001-08-14
AT413647B (de) 2006-04-15
IL142762A0 (en) 2002-03-10
SK7162001A3 (en) 2001-10-08
SI1133298T1 (sl) 2007-10-31
JP2002530338A (ja) 2002-09-17
CA2348876A1 (en) 2000-06-02
ZA200103927B (en) 2002-05-15
DE69935609T2 (de) 2007-12-06
ES2285866T3 (es) 2007-11-16
NO20012526D0 (no) 2001-05-23
EP1133298A1 (en) 2001-09-19
CZ20011845A3 (cs) 2001-08-15
KR20010080566A (ko) 2001-08-22
HUP0104412A3 (en) 2002-08-28
AT500135A1 (de) 2005-11-15
AU1654400A (en) 2000-06-13
PE20001326A1 (es) 2000-12-12
YU34601A (sh) 2004-09-03
ATE357237T1 (de) 2007-04-15
NO20012526L (no) 2001-05-23
AU759517B2 (en) 2003-04-17
US6727243B1 (en) 2004-04-27
CN1330546A (zh) 2002-01-09
NZ511588A (en) 2003-08-29
DE69935609D1 (de) 2007-05-03
ATA198998A (de) 2005-09-15
TWI229603B (en) 2005-03-21
AR021405A1 (es) 2002-07-17
EP1133298B1 (en) 2007-03-21
RU2248794C2 (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
TR200101417T2 (tr) Sefuroksim aksetil içeren kompozisyonlar.
PT904110E (pt) Dadores de oxido nitrico capazes de reduzir a toxicidade causada por farmacos
BR0112094A (pt) Produtos de confeitaria contendo ingredientes ativos
TR200101412T2 (tr) Yeni bileşikler.
AU2003269327A1 (en) Tetrahydroquinoline derivatives as crth2 antagonists
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
DK354785D0 (da) Stabile salte af s-adenosyl-l-methionin med polyanioner
TR200101339T2 (tr) Potasyum kanal modülatörleri olarak 3-yer-alanlı-4-arilkinolin-2-on türevleri, 3,4-okzadiazolon türevleri
TR200200649T2 (tr) Farmasötik özelliklere sahip olan yeni aminodikarboksilik asit türevleri
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
BR9801652A (pt) Resorcinil-triazinas
AU6542986A (en) Pyridyl-methylthio substituted benzimidazoles
BR9808366A (pt) Derivados de ácido hidroxâmico substituìdo com aril ou heteroaril sulfonamidas; processo para sua preparação e seu uso como produtos farmacêuticos
DE60229417D1 (de) Setzungen auf basis von pyrogenisch hergestelltem siliziumdioxid
NZ519717A (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
SE0302129D0 (sv) Farmaceutiska kompositioner med antibiotisk aktivitet
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
ATE259813T1 (de) Triazolopyrimidinderivate
TR200200081T2 (tr) Aşındırıcı sıvı temizlik bileşimleri.
TR200200831T2 (tr) Siklesonid içeren sulu farmasötik kompozisyon
ATE405275T1 (de) Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
BR0113070A (pt) Composições farmacêuticas contendo carbonato de lìtio
AU6749401A (en) Use of aloe-emodin in the treatment of neuroectodermal tumors
AU3138389A (en) Peptides with pharmaceutical activity
AU8678682A (en) Aminoglycoside derivatives